Future of Medicine·10 min read·

A Batch of One: Cell and Gene Therapy and the Hardest Supply Chain in Medicine

Cell and gene therapies are a 'batch of one' — made from a single patient's cells, shipped below -150°C, tied to one person by chain of identity. Why they rewrite cold chain and GDP, and how the UAE is building the capability to serve the region.

V-Sentinel Editorial · Healthcare supply chain compliance, GCC

In 2023, a team in Abu Dhabi took white blood cells from an eleven-year-old boy with leukaemia, re-engineered them in a laboratory so they could recognise and kill his cancer, and infused them back into his body. It was his best remaining option after chemotherapy had failed. The medicine did not come off a production line. There was a single dose of it in the world, it was made from his own cells, and it would have been useless to anyone else. This was the UAE's first locally manufactured CAR-T cell therapy, produced at the Abu Dhabi Stem Cells Center — and it is a glimpse of where a meaningful slice of medicine is heading.1

For a supply chain, this is a different universe. The pharmaceutical logistics the industry was built around moves identical, interchangeable units: a pallet of paracetamol is a pallet of paracetamol, and one box is as good as the next — the model that scales effortlessly to a mass-market product like the new oral obesity pill. A cell therapy is the opposite. It is a batch of one, tied irreversibly to a single patient, with parts of its journey time-critical to the hour and a temperature requirement far below anything in a conventional cold chain. It is widely regarded as one of the most complex supply chains in healthcare.2 And it is no longer a Western-hospital curiosity. It is being built, and run, in the Gulf.

This article is for supply chain, quality and operations leaders who still think of advanced therapies as something that happens elsewhere. The argument is that the logistics of personalised medicine are arriving in the UAE faster than most distribution operations are ready for — and that they rewrite the rules of cold chain, traceability and Good Distribution Practice that the whole sector runs on.

The medicine is the patient

Two families of treatment sit behind the headline. A cell therapy such as CAR-T takes a patient's own immune cells, re-programmes them — adding a chimeric antigen receptor that lets them find and destroy cancer — multiplies them, and returns them. A gene therapy goes a step deeper and edits the genetic instructions themselves. In January 2026 Abu Dhabi crossed that second threshold, administering the UAE's first CRISPR-based gene therapy for inherited blood disorders: Casgevy, in which a patient's own blood stem cells are collected, edited outside the body with CRISPR-Cas9, and reinfused to treat sickle cell disease and beta thalassaemia. It was delivered through a collaboration between Yas Clinic Khalifa City, the Abu Dhabi Stem Cells Center and Vertex Pharmaceuticals, under the oversight of the Department of Health — Abu Dhabi.3

What both families share, and what matters for everyone downstream, is that the product is no longer separable from the person. The starting material is harvested from one patient; the finished dose is returned to that same patient and no other. The supply chain is not delivering a product to a patient. It is carrying a part of the patient out, and a more powerful part of them back.

Why the supply chain breaks

For an operation built on interchangeable stock, four features of this model break the usual playbook at once.

The first is chain of identity. Because the dose is made from and for one person, a mix-up is not a quality deviation — it is potentially fatal, and irreversible. The chain of identity begins at the moment of cell collection and must follow that single dose, unbroken and verifiable, through every handoff to the moment of infusion.4 Ordinary pharmaceutical traceability proves a batch is genuine. This proves a dose belongs to this patient. It is a different and far less forgiving discipline.

The second is the vein-to-vein clock. The journey runs from the patient's vein, out to a manufacturing facility, and back to the same vein. Fresh cells collected by apheresis are time-critical — typically within a tightly controlled window measured in hours rather than days, defined by each therapy's own protocol — and a thawed final dose is infused at the bedside without delay.5 There is no safety stock, no second pallet in the warehouse, no reorder. If a shipment is lost, there is nothing to replace it with, and the patient may not have time to start again.

The third is the temperature. Many autologous cell therapies are routinely stored and transported below -150°C, in vapour-phase liquid nitrogen, and moved on the day of infusion in specialised "dry shippers."6 That is colder than the lowest temperature ever recorded on the surface of the Earth — around -89°C — and an order of magnitude beyond the 2-8°C cold chain that already tests most warehouses through a Gulf summer. The gap between the payload and the environment has rarely been wider.

The fourth is irreversibility. In conventional distribution, a temperature excursion triggers an investigation and, often, a replacement from stock. Here, a significant excursion can compromise the only dose that will ever exist for that patient. The cost of a logistics failure is not written off against a batch. It is borne by a person.

What the UAE has already built

None of this is hypothetical in the Emirates. The Abu Dhabi Stem Cells Center, part of the PureHealth group and accredited by the international cellular-therapy bodies FACT and AABB, operates GMP-grade manufacturing — one of a small number of advanced cell-therapy manufacturing facilities in the region.7 It produced the country's first locally manufactured CAR-T therapy in 2023, went on to deliver the Middle East's first CAR-T treatment for the autoimmune disease lupus, and has built a wider regenerative-medicine programme around it. The January 2026 Casgevy administration added gene editing to that capability. A dedicated CAR-T manufacturing facility has also been established at Burjeel Medical City in partnership with Caring Cross, explicitly to bring down cost and widen regional access.8

The UAE is building a hub, not just a treatment room

The deeper story is not that these therapies are reaching UAE patients. It is that the UAE is choosing to make them, not only administer them — and to make them at a scale meant to serve more than its own population. In 2026 the Department of Health — Abu Dhabi, M42 and PureHealth set out plans with GEMMABio Therapeutics to establish dedicated gene-therapy manufacturing and research centres expressly so that patients from across the MENA region could access these treatments and trials; separately, LIFEPharma, a VPS Health spin-off, committed more than AED 100 million to advanced-biologics manufacturing within a KEZAD industrial expansion.9

The strategic significance is easy to miss. For most of CAR-T's history, a hospital outside the United States or Europe had to ship a patient's cells to another continent to be manufactured, then wait for them to come back — a vein-to-vein loop stretched across the globe, every additional border and flight a fresh point of failure. Building manufacturing inside the UAE collapses that loop to something closer to a domestic journey. Building it at a scale meant to serve the wider Gulf turns a clinical capability into a regional supply-chain position — and that is, at its core, a logistics position. The hub that can manufacture, store and move advanced therapies reliably for the region becomes very hard to displace. The third-party logistics market that serves these therapies is expanding quickly; analyst estimates suggest the global segment will roughly double between the middle of this decade and 2030, and a region that hosts the manufacturing is positioned to capture more of it.10

Where this stretches GDP — and where the work sits

These therapies do not escape regulation; they stretch it. The Emirates Drug Establishment's federal mandate already reaches beyond conventional medicines to stem cells and advanced products, and clinical delivery sits under emirate health authorities — the Department of Health — Abu Dhabi in the Casgevy case.11 But the Good Distribution Practice framework most distributors run was written for boxes: temperature mapping, excursion management, documented batch traceability. Advanced therapies bend almost every one of those controls into a more demanding shape.

Traceability becomes chain of identity. Conventional GDP traceability proves a batch is authentic and was stored correctly. An autologous therapy demands more — an unbroken, verifiable link between the cells that left a specific patient and the dose returned to that same patient, maintained across every custodian and every border. Chain of custody, the record of who held the product and under what conditions, now sits on top of chain of identity rather than in place of it.

Validation becomes cryogenic. Mapping a 2-8°C cold room is demanding; qualifying a -150°C vapour-phase shipper — its hold time, its alarms, its contingency on a delayed flight — is a different order of work, and the calibration and monitoring evidence an EDE inspector expects grows with it.

Release becomes time-critical. In conventional distribution, a product waits in quarantine until it is released. Here the clock is running on a living dose, and the batch-release decision — the deviation review, the stability assessment after any excursion, the responsible person's sign-off — must be made at speed, against a patient's treatment schedule, without cutting the corners that make the sign-off meaningful. A deviation on a pallet of tablets is a quality event. A deviation on a batch of one is a clinical emergency.

None of this is beyond the reach of a well-run Gulf operation, but none of it is improvised the week a contract is signed. The competence that moves a vaccine reliably across a Gulf summer is the foundation for the competence that will move a -150°C autologous dose — and only the foundation. The operators who begin building chain-of-identity discipline, cryogenic validation and time-critical release now will hold a capability their competitors cannot conjure on demand. The ones that wait will be shut out of the highest-value, fastest-growing segment of the market by the very thing that makes it valuable: that it is unforgiving.

The supply chain becomes the therapy

The clearest way to see where medicine is going is to watch what it asks of the people who move it. As treatment becomes personal — a dose grown from one patient's cells, an edit made to one patient's genome — the supply chain stops being a back-office function and becomes part of the therapy itself. A batch of one has no margin for error, and no second chance to get the logistics right.

The Gulf has chosen to build this capability at home rather than import it dose by dose. The operators who treat cold chain and chain of identity as a core competence, rather than a compliance checkbox, are the ones who will be trusted to carry the medicine that is a person.

V-Sentinel works with UAE healthcare operators on the cold chain, traceability and GDP foundations that advanced therapies depend on. Use our GDP Readiness Assessment to see where your operation stands. Senior expert review, AI-powered delivery.

Sources

Footnotes

  1. Abu Dhabi Media Office / Gulf News, Abu Dhabi Stem Cells Center manufactures the UAE's first CAR-T cell (first locally manufactured CAR-T therapy; eleven-year-old leukaemia patient; 2023), mediaoffice.abudhabi / gulfnews.com. ↩

  2. McKinsey & Company, Driving the next wave of innovation in CAR T-cell therapies; Cell & Gene Therapy Insights, The Evolving CAR-T Therapy Supply Chain (autologous "one-batch, one-patient" model; vein-to-vein handoffs widely described as among the most complex in healthcare), mckinsey.com / insights.bio. ↩

  3. The National / Khaleej Times, Abu Dhabi administers first gene-therapy injection for patients with inherited blood disorders (Casgevy; ex vivo CRISPR-Cas9 editing of the patient's own stem cells for sickle cell disease and beta thalassaemia; 5 January 2026; Yas Clinic Khalifa City, Abu Dhabi Stem Cells Center and Vertex Pharmaceuticals, under Department of Health — Abu Dhabi oversight), thenationalnews.com / khaleejtimes.com. ↩

  4. Cell & Gene Therapy Insights; McKinsey & Company (chain of identity begins at cell collection and follows the single dose through manufacturing to final dosing; chain of custody layered on top), insights.bio / mckinsey.com. ↩

  5. IntuitionLabs / industry supply-chain analyses (fresh apheresis material is time-critical, with manufacturer-defined windows typically measured in hours; thawed product infused without delay). Specific timeframes vary by therapy and manufacturer. ↩

  6. The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of CAR-T Therapy Products (PubMed); Cryosite (storage below -150°C in vapour-phase liquid nitrogen; transport in dry shippers on day of infusion). The -89°C figure is the coldest reliably recorded natural surface temperature on Earth (Antarctica). pubmed.ncbi.nlm.nih.gov / cryosite.com. ↩

  7. Abu Dhabi Media Office / PureHealth, Abu Dhabi Stem Cells Center (FACT and AABB accreditation; integrated clinical care, research and biomanufacturing; first CAR-T therapy for lupus in the Middle East), mediaoffice.abudhabi / purehealth.ae. ↩

  8. Grand View Research / regional reporting, UAE cell and gene therapy manufacturing (CAR-T manufacturing facility at Burjeel Medical City with Caring Cross to reduce cost and improve regional access), grandviewresearch.com. ↩

  9. Department of Health — Abu Dhabi, DoH, M42, PureHealth and GEMMABio Therapeutics plan to advance gene therapies (dedicated manufacturing and research centres enabling patients from across the MENA region to access gene therapies), doh.gov.ae; HealthCare Middle East & Africa, LIFEPharma launches US$27.2M UAE cell and gene therapy spin-off amid KEZAD expansion (May 2026), healthcaremea.com. ↩

  10. Grand View Research / Towards Healthcare, Cell and Gene Therapy Third-Party Logistics Market (global market estimated at ~USD 10.7 billion in 2024, projected to roughly USD 20 billion by 2030). Market-sizing figures are analyst estimates and vary by source. ↩

  11. Emirates Drug Establishment, About EDE (federal remit covering medical and pharmaceutical products including stem cells and advanced products), ede.gov.ae; clinical delivery under emirate health authorities, per the Department of Health — Abu Dhabi oversight of the January 2026 gene-therapy administration. ↩

← Back to Insights